Screening guidelines for colorectal cancer: What should we advocate to our patients?

Amy Wang, David Lieberman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Colorectal cancer is the second leading cause of cancer death in the United States. Several medical societies have provided formal guidelines recommending various modalities for average-risk populations. These recommendations universally support the use of high-sensitivity fecal occult blood tests, flexible sigmoidoscopy, and colonoscopy for screening. However, there are differences in the support for fecal DNA stool testing and CT colonography. Regardless of the test, it is imperative that physicians and their patients be aware of the characteristics, benefits, and limitations of each modality. This review discusses the recommendations and provides an up-to-date review of the literature for colorectal cancer screening.

Original languageEnglish (US)
Pages (from-to)8-15
Number of pages8
JournalCurrent Colorectal Cancer Reports
Volume6
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Colorectal Neoplasms
Guidelines
Computed Tomographic Colonography
Sigmoidoscopy
Occult Blood
Medical Societies
Hematologic Tests
Colonoscopy
Early Detection of Cancer
Cause of Death
Physicians
DNA
Population
Neoplasms

Keywords

  • Colonoscopy
  • Colorectal cancer
  • CT colonography
  • Fecal ocult blood tests
  • Screening tests

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Screening guidelines for colorectal cancer : What should we advocate to our patients? / Wang, Amy; Lieberman, David.

In: Current Colorectal Cancer Reports, Vol. 6, No. 1, 01.2010, p. 8-15.

Research output: Contribution to journalArticle

@article{18a2b08fb51946058b47a0834930937d,
title = "Screening guidelines for colorectal cancer: What should we advocate to our patients?",
abstract = "Colorectal cancer is the second leading cause of cancer death in the United States. Several medical societies have provided formal guidelines recommending various modalities for average-risk populations. These recommendations universally support the use of high-sensitivity fecal occult blood tests, flexible sigmoidoscopy, and colonoscopy for screening. However, there are differences in the support for fecal DNA stool testing and CT colonography. Regardless of the test, it is imperative that physicians and their patients be aware of the characteristics, benefits, and limitations of each modality. This review discusses the recommendations and provides an up-to-date review of the literature for colorectal cancer screening.",
keywords = "Colonoscopy, Colorectal cancer, CT colonography, Fecal ocult blood tests, Screening tests",
author = "Amy Wang and David Lieberman",
year = "2010",
month = "1",
doi = "10.1007/s11888-009-0036-3",
language = "English (US)",
volume = "6",
pages = "8--15",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Screening guidelines for colorectal cancer

T2 - What should we advocate to our patients?

AU - Wang, Amy

AU - Lieberman, David

PY - 2010/1

Y1 - 2010/1

N2 - Colorectal cancer is the second leading cause of cancer death in the United States. Several medical societies have provided formal guidelines recommending various modalities for average-risk populations. These recommendations universally support the use of high-sensitivity fecal occult blood tests, flexible sigmoidoscopy, and colonoscopy for screening. However, there are differences in the support for fecal DNA stool testing and CT colonography. Regardless of the test, it is imperative that physicians and their patients be aware of the characteristics, benefits, and limitations of each modality. This review discusses the recommendations and provides an up-to-date review of the literature for colorectal cancer screening.

AB - Colorectal cancer is the second leading cause of cancer death in the United States. Several medical societies have provided formal guidelines recommending various modalities for average-risk populations. These recommendations universally support the use of high-sensitivity fecal occult blood tests, flexible sigmoidoscopy, and colonoscopy for screening. However, there are differences in the support for fecal DNA stool testing and CT colonography. Regardless of the test, it is imperative that physicians and their patients be aware of the characteristics, benefits, and limitations of each modality. This review discusses the recommendations and provides an up-to-date review of the literature for colorectal cancer screening.

KW - Colonoscopy

KW - Colorectal cancer

KW - CT colonography

KW - Fecal ocult blood tests

KW - Screening tests

UR - http://www.scopus.com/inward/record.url?scp=79952709456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952709456&partnerID=8YFLogxK

U2 - 10.1007/s11888-009-0036-3

DO - 10.1007/s11888-009-0036-3

M3 - Article

AN - SCOPUS:79952709456

VL - 6

SP - 8

EP - 15

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 1

ER -